Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery
Public ClinicalTrials.gov record NCT03319082. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IV Observational Registry to Assess the Safety and Durability of Effect of Corneal Collagen Cross-linking With Photrexa Viscous, Photrexa, and the KXL System in Patients With Corneal Ectasia Following Refractive Surgery
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objectives of this post market registry are to evaluate the safety and durability of treatment effect up to 3 years following cross-linking performed with Photrexa Viscous (riboflavin 5'- phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'- phosphate ophthalmic solution), and the KXL System in patients with corneal ectasia following refractive surgery.
Study identification
- NCT ID
- NCT03319082
- Recruitment status
- Not listed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 3, 2017
- Primary completion
- Jan 31, 2026
- Completion
- Jan 31, 2026
- Last update posted
- Feb 22, 2024
2017 – 2026
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University School of Medicine | Palo Alto | California | 94303 | Recruiting |
| Chu Vision Institute, P.A. | Bloomington | Minnesota | 55420 | Recruiting |
| Vance Thompson Vision - MT | Bozeman | Montana | 59718 | Recruiting |
| Vance Thompson Vision - ND | West Fargo | North Dakota | 58078 | Recruiting |
| Comprehensive EyeCare of Central Ohio | Westerville | Ohio | 43082 | Recruiting |
| Vantage Eye Care, LLC | Bala-Cynwyd | Pennsylvania | 19004 | Recruiting |
| Carolina Cataract & Laser Center | Ladson | South Carolina | 29456 | Recruiting |
| Slade & Baker Vision | Houston | Texas | 77027 | Recruiting |
| Hoopes Vision | Draper | Utah | 84020 | Recruiting |
| See Clearly Vision Group | McLean | Virginia | 22102 | Recruiting |
| Northwest Eye Surgeons | Seattle | Washington | 98133 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03319082, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 22, 2024 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03319082 live on ClinicalTrials.gov.